Clin Gastroenterology H: Patients with inflammatory bowel disease are significantly less likely to have a intestinal excision after receiving biological agents.

Background and target 50 to 80 percent of Crohn's disease (CD) patients and 10 to 30 percent of ulcerative colitis (UC) patients need surgery throughout their lives.
may change the progression of the disease, but the effect of biologics on surgical rates is not clear in the patient population.
study explores the effects of biologics on the prevalence of CD and UC surgery.
methodology researchers used the U.S. Medical Database to conduct retrospective studies of all patients diagnosed with CD or UC between 2015 and 2020 and treated with any biological agent.
observations were the association between biologic therapy and the prevalence of intestinal excision.
, risk factors associated with surgery in biologics and IBD patients were explored.
32904480 patients in the results medical database, the researchers identified 140,540 CD patients and 115,260 UC patients, of whom 25,840 (18%) and 9,050 (7.8%) were treated with biologics, respectively.
the prevalence of intestinal excision (9.3%) was significantly lower in CD patients treated with biologics (p .lt;0.001) than in CD patients who were not treated with biologics.
, UC patients treated with biologics were significantly less likely to receive colonectomy (11.0% VS 7.3% ;p slt;0.001).
smoking, Thyrobacteria infections and diseases are associated with CD bowel removal.
infections with colon tumors and thyrobacteria were associated with UC colonectomy.
this study confirms that patients with inflammatory bowel disease (IBD) who have never been treated with biologics are significantly less likely to have an intestinal excision than those treated with biological agents.
.